Collectively, the present study suggests that inhibiting K-Ras can significantly delay the malignant behavior of CRPC cells and that the combined therapy of inhibitor 9 and ADT with or without chemotherapy may supply a new treatment strategy for patients with refractory prostate cancer. This evidence concerns the gene KRAS and prostate carcinoma.